ADPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Adaptive Biotechnologies's change in receivables for the quarter that ended in Dec. 2023 was $-6.8 Mil. It means Adaptive Biotechnologies's Accounts Receivable increased by $6.8 Mil from Sep. 2023 to Dec. 2023 .
Adaptive Biotechnologies's change in receivables for the fiscal year that ended in Dec. 2023 was $2.0 Mil. It means Adaptive Biotechnologies's Accounts Receivable declined by $2.0 Mil from Dec. 2022 to Dec. 2023 .
Adaptive Biotechnologies's Accounts Receivable for the quarter that ended in Dec. 2023 was $38.0 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Adaptive Biotechnologies's Days Sales Outstanding for the three months ended in Dec. 2023 was 75.67.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Adaptive Biotechnologies's liquidation value for the three months ended in Dec. 2023 was $29.2 Mil.
The historical data trend for Adaptive Biotechnologies's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Change In Receivables | Get a 7-Day Free Trial | -7.82 | 2.61 | -7.36 | -22.65 | 2.03 |
Adaptive Biotechnologies Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Change In Receivables | Get a 7-Day Free Trial | -13.51 | 9.09 | -0.62 | 0.33 | -6.77 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies (NAS:ADPT) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Adaptive Biotechnologies's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 37.969 | / | 45.784 | * | 91 |
= | 75.67 |
2. In Ben Graham's calculation of liquidation value, Adaptive Biotechnologies's accounts receivable are only considered to be worth 75% of book value:
Adaptive Biotechnologies's liquidation value for the quarter that ended in Dec. 2023 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 346.401 | - | 352.856 | + | 0.75 * 37.969 | + | 0.5 * 14.448 |
= | 29.2 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Adaptive Biotechnologies's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Kyle Piskel | officer: Principal Accounting Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Nitin Sood | officer: Chief Commercial Officer, MRD | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Tycho Peterson | officer: Chief Financial Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109 |
R Mark Adams | officer: Chief Operating Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Michelle Renee Griffin | director | 19723 NE 65TH LANE, KIRKLAND WA 98033 |
Stacy L Taylor | officer: SVP and General Counsel | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102 |
Leslie Trigg | director | C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112 |
Kevin T Conroy | director | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Robert Hershberg | director | 3005 FIRST AVENUE, SEATTLE WA 98121 |
Peter M Neupert | director | 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005 |
Sharon Benzeno | officer: Chief Commercial Ofc Imm Med | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Harlan S Robins | officer: Chief Scientific Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Francis Lo | officer: Chief People Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Michael J Pellini | director | 222 DUTTON MILL RD, WILLISTOWN PA 19380 |
Chad M Robins | director, officer: CEO and Chairman | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
From GuruFocus
By PurpleRose PurpleRose • 07-15-2022
By Marketwired • 11-02-2023
By Tiesvg Tiesvg • 12-27-2022
By Marketwired • 07-10-2023
By PurpleRose PurpleRose • 07-15-2022
By PurpleRose PurpleRose • 07-28-2022
By PurpleRose PurpleRose • 07-12-2022
By PurpleRose PurpleRose • 08-03-2022
By Marketwired • 08-30-2023
By Stock market mentor Stock market mentor • 01-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.